BUZZ-Brystol Myers rises after BofA upgrades rating to "buy"** Drug maker Brystol Myers Squibb's BMY.N shares rise 2.4% to $53.64 after BofA Global Research upgrades rating to "buy" from "neutral"
** Brokerage raises PT to $61 from $52, a 16.4% upside to stock's last close
** Attributes upgrade to co's R&D pipeline outlook; says 2026 a big year for BMY's anti-psychotic drug, Cobenfy
** "We estimate Cobenfy, despite a slow first year launch, can get to $3bn US peak in schizophrenia alone" - BofA
** 10 of 30 brokerages rate the stock "buy" or higher, 18 "hold" and 2 "sell"; median PT is $54 - LSEG data
** Including session moves, stock down 5.3% YTD
(Reporting by Utkarsh Tushar Hathi)
((utkarshtushar.hathi@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.